Merck & Co., Inc. (MRK) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncolog...
Merck & Co., Inc. (MRK) currently trades at a P/E ratio of 40.72 (historical range: 10.65–42.28, median: 16.33), placing it at the 98th percentile — expensive relative to its history, P/S ratio of 5.53 (range: 2.90–5.74, 98th percentile — expensive relative to its history), EV/EBITDA of 15.71 (range: 11.75–42.76, 38th percentile).
Over the historical period (2024-08-30 to 2026-08-28), Merck & Co., Inc.'s P/E ratio has expanded by 30% over the observed period (from an average of 17.0 to 22.2).
Merck & Co., Inc. appears overvalued relative to its own historical valuation range, trading at elevated multiples across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 40.72 | 10.65 | 16.33 | 42.28 | 98th | expensive relative to its history |
| P/S Ratio | 5.53 | 2.90 | 4.01 | 5.74 | 98th | expensive relative to its history |
| EV/EBITDA | 15.71 | 11.75 | 17.53 | 42.76 | 38th | below its historical average |
| FCF Yield | 0.01 | 0.01 | 0.02 | 0.09 | 14th | expensive relative to its history |